Recce Pharmaceuticals

(ASX) RCE

Current PriceA$0.50

Market CapA$144.59M

Since IPO (2016)+70%

5 Year-52%

1 Year+49%

1 Month+2%

Recce Pharmaceuticals Financials at a Glance

Market Cap

A$144.59M

Revenue (TTM)

A$10.16M

Net Income (TTM)

-A$48.19M

EPS (TTM)

-A$0.11

P/E Ratio

-4.39

Dividend

A$0.00

Beta (Volatility)

-0.07 (Low)

Dividend

A$0.00

Beta (Volatility)

-0.07 (Low)

Price

A$0.50

Volume

85,743

Open

A$0.50

Price

A$0.50

Volume

85,743

Open

A$0.50

Previous Close

A$0.50

Daily Range

A$0.49 - A$0.50

52-Week Range

A$0.29 - A$0.73

Estimated Earnings Date

Aug 28, 2026

Dividend

A$0.00

Beta (Volatility)

-0.07 (Low)

Price

A$0.50

Volume

85,743

Open

A$0.50

Previous Close

A$0.50

Daily Range

A$0.49 - A$0.50

52-Week Range

A$0.29 - A$0.73

Estimated Earnings Date

Aug 28, 2026

RCE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Recce Pharmaceuticals

Industry

Pharmaceuticals

Sector

Health Care

CEO

James Graham

Website

www.recce.com.au

Headquarters

Sydney, NSW 2000, AU

RCE Financials

Key Financial Metrics (TTM)

Gross Margin

-3%

Operating Margin

-39%

Net Income Margin

-54%

Return on Equity

Return on Capital

Return on Assets

-15%

Earnings Yield

-22.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$144.59M

Shares Outstanding

289.18M

Volume

85.74K

Avg. Volume

99.22K

Financials (TTM)

Gross Profit

-A$2.94M

Operating Income

-A$22.88M

EBITDA

-A$20.33M

Operating Cash Flow

-A$20.44M

Capital Expenditure

-A$26.35K

Free Cash Flow

-A$20.47M

Cash & ST Invst.

A$10.45M

Total Debt

A$10.77M

Recce Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$67.05K

-103.1%

Gross Margin

0.00%

N/A

Market Cap

A$144.59M

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-A$16.56M

-121.9%

EBITDA

-A$13.68M

-47.5%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

A$602.99K

-85.0%

Total Debt

A$11.26M

+5565.5%

Accounts Receivable

A$27.93K

-81.7%

Inventory

A$0.00

N/A

Long Term Debt

A$9.51M

+12333.9%

Short Term Debt

A$1.75M

+1328.4%

Return on Assets

-14.82%

N/A

Return on Invested Capital

2.37%

N/A

Free Cash Flow

-A$10.26M

-54.9%

Operating Cash Flow

-A$10.23M

-57.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SDI.AXSDI Limited

SDI.AXSDI LimitedA$1.36-0.37%

ACW.AXActinogen Medical Limited

ACW.AXActinogen Medical LimitedA$0.03+0.00%

ATH.AXAlterity Therapeutics Limited

ATH.AXAlterity Therapeutics LimitedA$0.50+11.24%

ILA.AXIsland Pharmaceuticals Limited

ILA.AXIsland Pharmaceuticals LimitedA$0.38+7.04%

ALA.AXArovella Therapeutics Limited

ALA.AXArovella Therapeutics LimitedA$0.07+1.52%

PAR.AXParadigm Biopharmaceuticals Limited

PAR.AXParadigm Biopharmaceuticals LimitedA$0.15+3.45%

BIO.AXBiome Australia Limited

BIO.AXBiome Australia LimitedA$0.28+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$160.95+0.19%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

NOKNokia

NOKNokia$14.80+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.46-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

Questions About RCE

What is the current price of Recce Pharmaceuticals?

Recce Pharmaceuticals is trading at A$0.50 per share.

What is the 52-week range for Recce Pharmaceuticals?

Over the past 52 weeks, Recce Pharmaceuticals has traded between A$0.29 and A$0.73.

How much debt does Recce Pharmaceuticals have?

As of the most recent reporting period, Recce Pharmaceuticals reported total debt of A$10.77M.

How much cash does Recce Pharmaceuticals have on hand?

Recce Pharmaceuticals reported A$10.45M in cash and cash equivalents in its most recent financial results.

What is Recce Pharmaceuticals’s dividend yield?

Recce Pharmaceuticals does not currently have a dividend yield.

Recce Pharmaceuticals

Recce Pharmaceuticals Financials at a Glance

RCE News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Recce Pharmaceuticals

RCE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Recce Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RCE

What is the current price of Recce Pharmaceuticals?

What is the 52-week range for Recce Pharmaceuticals?

How much debt does Recce Pharmaceuticals have?

How much cash does Recce Pharmaceuticals have on hand?

What is Recce Pharmaceuticals’s dividend yield?

Premium Investing Services